EPO Biomarkers Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

EPO Biomarkers Market Analysis

The EPO Biomarkers Market size is estimated at USD 66.38 billion in 2024, and is expected to reach USD 86.70 billion by 2029, growing at a CAGR of 5.49% during the forecast period (2024-2029).

Erythropoietin (EPO) biomarkers play a vital role in diagnosing, prognosis, and managing conditions related to erythropoiesis, such as anemia and chronic kidney disease. The increasing prevalence of chronic diseases, increasing research studies in diagnostic technologies, and surge in demand for personalized medicine contribute to the market growth during the forecast period. For instance, as per a study published by the Epidemiology of Chronic Disease and Prevention in July 2023, chronic kidney disease (CKD) affects 10%-15% of the worldwide population, and more than 2 million people globally received treatment with dialysis or kidney transplants to stay alive in 2022. Of these, 20% are treated in 100 low-income countries, which comprise half of the world's population.

Similarly, per data published by the International Society of Nephrology in August 2023, the median CKD prevalence in Eastern and Central Europe was 12.8%, ranging from 9.3% in Cyprus to 16.8% in Estonia in 2022. Thus, the increasing prevalence of chronic kidney diseases is anticipated to drive the demand for biomarkers, which play a crucial role in diagnosing and treating these diseases.

Moreover, as per the data published by the Minority HIV/AIDS Fund in November 2023, over 39 million people lived with HIV in 2022 around the globe. Certain regions of the globe are disproportionately affected by HIV. There were 20.8 million people with HIV in Eastern and Southern Africa, 4.8 million in Western and Central Africa, 6.5 million in Asia-Pacific, and 2.3 million in Western and Central Europe in 2022. With the growing needs of this patient population, the government and pharmaceutical industries are focused on investing more in developing EPO biomarkers, which positively affect market growth.

Factors such as favorable healthcare regulations in developed economies and increasing research and development in EPO biomarker technology are expected to drive market growth during the forecast period. For instance, in June 2022, the research team at Kyoto University unveiled the distinctive behaviors of erythropoietin (Epo)-producing cells. This discovery provides valuable insights into the mechanism behind renal anemia, a prevalent complication of chronic kidney disease resulting from the kidneys' inadequate production of EPO. Such studies are expected to expand the research and development activities related to EPO biomarkers to introduce innovative therapies, thereby surging its demand in the upcoming years.

Moreover, biomarkers offer valuable insights into disease pathogenesis and therapeutic efficacy, enabling personalized approaches and better clinical outcomes. As the demand for personalized medicine surges, the introduction of novel EPO biomarkers in the market significantly increases. For instance, as per a study published by Scientific Reports in September 2023, EPO levels were decreased in anemia of inflammation (AI) or anemia of unknown etiology (AUE) population while increased in bone marrow disease-associated anemia, suggesting its role in differentiating bone marrow disease in elderly anemic patients with unclear etiology. Thus, growing clinical studies highlighting the significance of EPO markers in diagnosing and treating various diseases are expected to open new growth avenues and expand its application in different therapeutic areas, thereby contributing to market growth.

Therefore, the market is anticipated to grow during the forecast period due to the increasing prevalence of chronic diseases, rise in research studies, and growing demand for personalized medicine. However, the limited availability of quality control testing laboratories and the risk of severe side effects may hinder the market's growth.

EPO Biomarkers Market Trends

The Cancer Segment by Application is Expected Witness Significant Growth During the Forecast Period

EPO Biomarkers Industry Segmentation

As per the scope of the report, EPO biomarkers are commonly used to treat end-stage renal (kidney) disease (ESRD) and anemia induced by multiple myeloma, cancer, and AIDS-associated anemia.

The market is segmented by type into erythropoietin alfa, erythropoietin beta, erythropoietin zeta, erythropoietin theta, and other types). By application, it is segmented into renal disorder, cancer, acquired immunodeficiency syndrome (AIDS), anemia of chronic inflammatory syndromes, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.

The report also offers the market size and forecasts for 17 regional countries. The report offers market sizing and forecasts based on the value (USD) for the above segments.